Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

The safety of elotuzumab, lenalidomide and dexamethasone in unresponsive multiple myeloma.

Posted by on Oct 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone. Some...

Read More

Evaluating mogamulizumab versus vorinostat in patients with T-cell lymphoma

Posted by on Oct 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of mogamulizumab (Poteligeo) versus vorinostat (Zolinza) in patients with previously treated cutaneous (skin) T-cell lymphoma (CTCL). This study concluded that mogamulizumab was well-tolerated and significantly more effective than vorinostat in these patients. Some background CTCL is a rare type of...

Read More

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Posted by on Sep 29, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...

Read More

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Posted by on Sep 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...

Read More

Evaluating venetoclax monotherapy for relapsed or refractory mantle cell lymphoma

Posted by on Sep 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...

Read More

Evaluating R-CyBorD for the treatment of relapsed non-Hodgkin’s lymphoma

Posted by on Sep 20, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the R-CyBorD (rituximab, cyclophosphamide, bortezomib, dexamethasone) regimen in patients with relapsed indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated in these patients. Some background There are many...

Read More

Sequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine

Posted by on Sep 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...

Read More

Can T-cell therapy treat unresponsive ALL?

Posted by on Sep 13, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the current evidence for the effect of changing genes in T-cells (a type of immune cell) to target cancer cells in acute lymphoblastic leukemia (ALL). The study found that these T-cells were safe and effective in the treatment of ALL. Some background Acute Lymphoblastic Leukemia is a type of bone marrow cancer...

Read More